NCT02078973View on ClinicalTrials.gov

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Nephropathy
Interventions
DRUG

15 mg tolvaptan

15 mg pr day for 1 day

DRUG

30 mg tolvaptan

30 mg pr day for 1 day

DRUG

45 mg tolvaptan

45 mg pr day for 1 day

DRUG

Placebo

1 tablet Unikalk pr day for 1 day

Trial Locations (1)

7500

Department of medical research, Holstebro

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

Regional Hospital Holstebro

OTHER

NCT02078973 - Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) | Biotech Hunter | Biotech Hunter